A retrospective cohort study to evaluate long-term impact of PCV-13 on pediatric community-acquired bacteremia and to optimally choose empiric antibiotic therapy for children with suspected community-acquired bacteremia
Latest Information Update: 10 Feb 2021
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
Most Recent Events
- 10 Feb 2021 New trial record
- 03 Feb 2021 Results published in the European Journal of Clinical Microbiology and Infectious Diseases